Investors
- Board of Directors
- Board Meeting
- AGM Notice
- EGM Notice
- Closure Of Trading Window
- Related Party Transactions
- Share Holding Patterns
- Quarterly Results
- Annual Report
- Annual Return
- Secretarial Compliance
- Disclosure U/r 30
- Voting Results
- Newspaper Publications
- Insider Trading Code
- Investors-2
Mail to: companysec@indswift.com[Email id of designated official for the purpose of grievance redressal]
Unaudited Financial Results for the Quarter ended 30th June, 2007 |
|||||
|---|---|---|---|---|---|
(RS. IN LACS) |
|||||
PARTICULARS |
QUARTER 30.06.07 |
QUARTER 30.06.06 |
QUARTER ENDED 31.03.06 |
YEAR ENDED 31.03.07 |
|
| INCOME FROM OPERATIONS | 11069.06 |
8342.46 |
5982.54 |
38556.60 |
|
| OTHER INCOME | 16.09 |
11.60 |
14.19 |
134.11 |
|
| TOTAL INCOME | 11085.15 |
8354.06 |
5996.73 |
38690.71 |
|
| TOTAL EXPENDITURE | 9631.31 |
7324.48 |
5394.37 |
33747.92 |
|
| DECREASE IN STOCK IN TRADE | -1530.43 |
229.35 |
-272.54 |
-1823.03 |
|
| CONSUMPTION OF RAW MATERIAL | 9628.69 |
5891.22 |
4821.58 |
30060.47 |
|
| COST OF SALES | 8098.26 |
6120.57 |
4549.04 |
28237.44 |
|
| STAFF COST | 369.53 |
289.87 |
219.93 |
1372.04 |
|
| OTHER EXPENSES | 1163.52 |
914.04 |
625.40 |
4138.44 |
|
| INTEREST | 542.88 |
330.10 |
288.84 |
1760.64 |
|
| DEPRECIATION | 110.00 |
68.15 |
37.20 |
304.85 |
|
| PROFIT BEFORE TAX | 800.96 |
631.33 |
276.32 |
2877.30 |
|
| PROVISION FOR TAX(INCL.FBT) | 100.75 |
78.68 |
22.50 |
355.82 |
|
| PROVISION FOR DEFFERED TAX | 150.00 |
52.15 |
126.02 |
292.40 |
|
| NET PROFIT | 550.21 |
500.50 |
127.80 |
2229.08 |
|
| SHARE CAPITAL | 743.57 |
743.57 |
743.57 |
743.57 |
|
| RESERVE EXCLUDING REVALUATION RESERVE | |||||
| E.P.S.(Rs.) RATE/SHARE Rs.2/- | 1.48 |
1.35 |
6.00 |
||
| AGGREGATE OF NON-PROMOTERS | |||||
| SHAREHOLDING | |||||
| No. OF SHARES | 23970124.00 |
24056475.00 |
23985890.00 |
||
| % AGE OF SHAREHOLDING | 64.47 |
64.71 |
64.51 |
||
Notes:- |
|||||
| 1. The Company has begun production of Soft Gelatine Capsules in its Unit IV at Baddi. The commercial production is expected to commence by August 2007. 2. The Company is going to launch a new division for marketing of medical devices and equipments. 3. During the quarter under review, the turnover of the Company grew by 32.68% and profit before tax grew by 26.87% as compaired to the same period in the previous year. 4. The Company is exclusively in Pharmaceutical business segment. 5.Investor Complaints for the quarter: Opening - Nil, Received -2, Redressed - 2, Closing Balance - Nil 6. The above results were reviewed by the audit committee and taken on record by the Board of Directors at its meeting held on 30.07.2007. |
|||||
On behalf of the Board
|
|||||
| Dated: 30th July 2007 | (Dr. Gopal Munjal) |
||||
| Place: Chandigarh | Chairman |
||||